Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Pharmacokinetics and Safety of iGlarLixi in Healthy Chinese Participants: Results of a Phase 1 Randomized Study

Open access
Xie, Panpan, He, Xuemei, Gao, Xin, Shuai, Mengmeng, Schmider, Wolfgang, Jiang, Alex, Yang, Na, Shi, Aixin · 2023 · Diabetes Therapy

Abstract

INTRODUCTION: The Chinese Diabetes Society recommends basal insulin and glucagon-like peptide-1 receptor agonists as an add-on therapy to first-line oral antihyperglycemic drugs for people with type 2 diabetes (T2D). Fixed-ratio combination of insulin glargine 100 U/ml (iGlar) and lixisenatide (iGlarLixi) is known to improve glycemic control in adults with T2D. However, the pharmacokinetics of iGlarLixi has not been evaluated in Chinese participants. The present study evaluated pharmacokinetics and safety of two iGlarLixi (10 U/10 μg and 30 U/15 μg) doses following single subcutaneous administration in healthy Chinese participants. METHODS: This was a Phase 1, single-center, open-label, parallel-group, randomized study in healthy Chinese adults who were randomized to receive a single dose of iGlarLixi with either 1:1 (10 U/10 μg) or 2:1 (30 U/15 μg) ratio of iGlar and lixisenatide. Primary objectives include assessment of pharmacokinetics of iGlar in iGlarLixi 30 U/15 μg group and the pharmacokinetics of lixisenatide in both the groups (iGlarLixi 10 U/10 μg and iGlarLixi 30 U/15 μg). Safety and tolerability were also assessed. RESULTS: of 3.25 and 2.00 h post-dose in both groups. The exposure increase was dose proportionate with a 1.5-fold increase in the lixisenatide dose. Adverse events observed were consistent with those previously reported with iGlar or lixisenatide. CONCLUSION: iGlarLixi administration resulted in early absorption of both iGlar and lixisenatide with a good tolerability profile in healthy Chinese participants. These results are consistent with the previously published data from other geographic regions. TRIAL REGISTRATION: U1111-1194-9411.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s13300-023-01434-0

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Study design. iGlarLixi a fixed-ratio combination (FRC) of iGlar and lixisenatide, IMP investigational medicinal product, PK pharmacokinetics
Fig. 1 Study design. iGlarLixi a fixed-ratio combination (FRC) of iGlar and lixisenatide, IMP investigational medicinal product, PK pharmacokineticsCC BY-NC · PubMed Central
Fig. 2 Plasma concentration-time profiles of lixisenatide following administration of iGlarLixi (10 U/10 µg and 30 U/15 µg). iGlarLixi a fixed-ratio combination (FRC) of iGlar and lixisenatide, h hour, LLOQ lower limit of quantification, SD standard deviation
Fig. 2 Plasma concentration-time profiles of lixisenatide following administration of iGlarLixi (10 U/10 µg and 30 U/15 µg). iGlarLixi a fixed-ratio combination (FRC) of iGlar and lixisenatide, h hour, LLOQ lower limit of quantification, SD standard deviationCC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 27 references

Research works printed but not linked: 3

  1. International Diabetes Federation: IDF Diabetes Atlas, 10th edition. Brussels, Belgium, International Diabetes Federation, 2021: https://diabetesatlas.org/. Accessed on March 01, 2022.
  2. Diabetes Branch of Chinese Medical Association: Guidelines for the Prevention and Treatment of Type 2 Diabetes in China (2020 Edition). Chin J Endocrinol Metab. 2021;37:311–98.
  3. Terauchi Y, Nakama T, Spranger R, et al. Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi 1:1) in Japanese patients with type 2 diabetes mellitus inadequately controlled on oral antidiabetic drugs: a randomized, 26-week, open-label, multicentre study: the LixiLan JP-O2 randomized clinical trial. Diabetes Obes Metab. 2020;22(Suppl 4):14–23. · DOI

Cited by

See all 2

Metadata

Authors
Xie, P., He, X., Gao, X., Shuai, M., Schmider, W., Jiang, A., Yang, N., & Shi, A.
Affiliations
  • Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
  • Sanofi (China) (CN)
  • Sanofi (Germany) (DE)
Corresponding author
Shi, Aixin
Venue
Diabetes Therapy
Published
2023-06-17
Volume
14
Issue
8
Pages
1387-1397
ISSN
  • 1869-6953 (ISSN-L)
  • 1869-6961
OpenAlex
W4381094640
Cited by
2
References
27
Citations by year
2025: 1 · 2024: 1
FWCI
0.41
Type
journal article
Language
en
Open access
Licence
Locations
  • Diabetes Therapy (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
Sanofi
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
Keywords
iGlarLixi, insulin glargine, lixisenatide, fixed-ratio combination, pharmacokinetics, type 2 diabetes, Chinese population, subcutaneous administration, dose proportionality, drug safety and tolerability, basal insulin, GLP-1 receptor agonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pharmacokinetics and Safety of iGlarLixi in Healthy Chinese Participants: Results of a Phase 1 Randomized Study. https://app.cochat.ai/papers/10.1007/s13300-023-01434-0
The paper
Xie, P., He, X., Gao, X., Shuai, M., Schmider, W., Jiang, A., Yang, N., & Shi, A. (2023). Pharmacokinetics and Safety of iGlarLixi in Healthy Chinese Participants: Results of a Phase 1 Randomized Study. Diabetes Therapy. https://doi.org/10.1007/s13300-023-01434-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.